title: Mycobacterium bovis abdominal aortic and femoral artery aneurysms following intravesical bacillus Calmette-Guérin therapy for bladder cancer.
abstract: BACKGROUND
  Infectious complications of intravesical bacillus Calmette-Guérin (BCG) therapy are rare, but these have included a handful of cases of mycotic aneurysm.
  
  
  RESULTS
  We present the case of a patient with a ruptured abdominal aortic aneurysm and a femoral artery aneurysm who had previously received intravesical BCG therapy for bladder carcinoma. Histopathologic examination of resected tissue revealed numerous acid-fast bacilli, and subsequent mycobacterial culture of blood and resected tissue revealed BCG strain Mycobacterium bovis.
  
  
  CONCLUSIONS
  Clinicians should be aware of the possible extravesical complications, albeit rare, of BCG therapy. Therapy should consist of combined medical and surgical management.
authors.affiliation: Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
authors.forename: Cecilia T
authors.initials: CT
authors.lastname: Costiniuk
authors.forename: Anton A
authors.initials: AA
authors.lastname: Sharapov
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Rose
authors.forename: John P
authors.initials: JP
authors.lastname: Veinot
authors.forename: Marc
authors.initials: M
authors.lastname: Desjardins
authors.forename: Tim M
authors.initials: TM
authors.lastname: Brandys
authors.forename: Kathryn N
authors.initials: KN
authors.lastname: Suh
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D000785:Aneurysm, Infected / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D000995:Antitubercular Agents / Q000627:therapeutic use; D017544:Aortic Aneurysm, Abdominal / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D001019:Aortic Rupture / Q000382:microbiology / Q000473:pathology / Q000601:surgery; D001500:BCG Vaccine / Q000009:adverse effects*; D005263:Femoral Artery / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008297:Male; D009163:Mycobacterium bovis / Q000302:isolation & purification* / Q000502:physiology; D016896:Treatment Outcome; D014381:Tuberculosis, Cardiovascular / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014613:Vaccines, Attenuated / Q000009:adverse effects
chemical_list: D000995:Antitubercular Agents; D001500:BCG Vaccine; D014613:Vaccines, Attenuated